Papers/PMID:37503812
Vitamin E supplementation in the treatment on nonalcoholic fatty liver disease (NAFLD): Evidence from an umbrella review of meta-analysis on randomized controlled trials.
Journal of digestive diseases2023The record
3 findings · 1 compound · 3 endpoints · 1 null
What it reported
How to read these marksWhat moved
2 findings
α-tocopherol — decreases alanine aminotransferase
Evidence strength: very limited.Findingreplicated ×4“By pooling ES based on the random-effects model, we found that vitamin E supplementation significantly decreased ALT (ES -6.47, 95% CI -11.73 to -1.22, P = 0.01), AST (ES -5.35, 95% CI -9.78 to -0.93, P = 0.01), degrees of fibrosis (ES -0.24, 95% CI -0.36 to -0.12, P < 0.001) and steatosis (ES -0.67, 95% CI -0.88 to -0.45, P < 0.001) in NAFLD patients, but had no effect on GGT.”
Quoted verbatim from Vitamin E supplementation in the treatment on nonalcoholic fatty liver disease (NAFLD): Evidence from an umbrella review of meta-analysis on randomized controlled trials.. - Study
- meta-analysis
- Population
- Patients with nonalcoholic fatty liver disease; umbrella review pooling six meta-analyses of randomized controlled trials
Vitamin E supplementation in the treatment on nonalcoholic fatty liver disease (NAFLD): Evidence from an umbrella review of meta-analysis on randomized controlled trials.2023PMID:3750381210.1111/1751-2980.13210Permalink
α-tocopherol — decreases aspartate aminotransferase
Evidence strength: very limited.Findingreplicated ×4“By pooling ES based on the random-effects model, we found that vitamin E supplementation significantly decreased ALT (ES -6.47, 95% CI -11.73 to -1.22, P = 0.01), AST (ES -5.35, 95% CI -9.78 to -0.93, P = 0.01), degrees of fibrosis (ES -0.24, 95% CI -0.36 to -0.12, P < 0.001) and steatosis (ES -0.67, 95% CI -0.88 to -0.45, P < 0.001) in NAFLD patients, but had no effect on GGT.”
Quoted verbatim from Vitamin E supplementation in the treatment on nonalcoholic fatty liver disease (NAFLD): Evidence from an umbrella review of meta-analysis on randomized controlled trials.. - Study
- meta-analysis
- Population
- Patients with nonalcoholic fatty liver disease; umbrella review pooling six meta-analyses of randomized controlled trials
Vitamin E supplementation in the treatment on nonalcoholic fatty liver disease (NAFLD): Evidence from an umbrella review of meta-analysis on randomized controlled trials.2023PMID:3750381210.1111/1751-2980.13210Permalink
What did not
1 finding
α-tocopherol — no detected effect on gamma-glutamyl transferase
Evidence strength: very limited.FindingNull result“By pooling ES based on the random-effects model, we found that vitamin E supplementation significantly decreased ALT (ES -6.47, 95% CI -11.73 to -1.22, P = 0.01), AST (ES -5.35, 95% CI -9.78 to -0.93, P = 0.01), degrees of fibrosis (ES -0.24, 95% CI -0.36 to -0.12, P < 0.001) and steatosis (ES -0.67, 95% CI -0.88 to -0.45, P < 0.001) in NAFLD patients, but had no effect on GGT.”
Quoted verbatim from Vitamin E supplementation in the treatment on nonalcoholic fatty liver disease (NAFLD): Evidence from an umbrella review of meta-analysis on randomized controlled trials.. - Study
- meta-analysis
- Population
- Patients with nonalcoholic fatty liver disease; umbrella review pooling six meta-analyses of randomized controlled trials
Vitamin E supplementation in the treatment on nonalcoholic fatty liver disease (NAFLD): Evidence from an umbrella review of meta-analysis on randomized controlled trials.2023PMID:3750381210.1111/1751-2980.13210Permalink